Immuneering’s (IMRX) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research note issued to investors on Monday,Benzinga reports. They currently have a $15.00 price target on the stock.

IMRX has been the topic of several other research reports. Chardan Capital reaffirmed a “buy” rating and set a $13.00 price target on shares of Immuneering in a report on Wednesday, January 8th. Morgan Stanley lowered Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $12.80.

Immuneering Stock Performance

Shares of IMRX opened at $1.90 on Monday. Immuneering has a 52 week low of $1.00 and a 52 week high of $7.68. The business has a 50-day simple moving average of $2.05 and a two-hundred day simple moving average of $1.79.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Marshall Wace LLP bought a new position in shares of Immuneering during the 2nd quarter valued at approximately $492,000. Renaissance Technologies LLC purchased a new stake in Immuneering in the 2nd quarter worth about $447,000. Acadian Asset Management LLC bought a new stake in Immuneering in the second quarter worth about $67,000. HighTower Advisors LLC boosted its position in shares of Immuneering by 21.4% during the third quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after buying an additional 9,400 shares during the period. Finally, Tidemark LLC bought a new position in shares of Immuneering during the third quarter valued at approximately $129,000. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.